Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Flex Pharma Inc    FLKS

FLEX PHARMA INC (FLKS)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/05/2017 12/06/2017 12/07/2017 12/08/2017 12/11/2017 Date
3.79(c) 3.77(c) 3.72(c) 3.72(c) 3.58(c) Last
37 195 8 744 23 561 46 605 15 618 Volume
-12.06% -0.53% -1.33% 0.00% -3.76% Change
More quotes
Financials ($)
Sales 2017 1,49 M
EBIT 2017 -36,7 M
Net income 2017 -36,8 M
Debt 2017 -
Yield 2017 -
Sales 2018 4,56 M
EBIT 2018 -50,2 M
Net income 2018 -40,8 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 43,2x
Capi. / Sales2018 14,1x
Capitalization 64,3 M
More Financials
Company
Flex Pharma, Inc. operates as a biotechnology company.It engages in developing treatments for exercise-associated muscle cramps, nocturnal leg cramps and spasms associated with severe neuromuscular conditions.The company operates through two segments: Consumer Operations and Drug Development.The... 
More about the company
Surperformance© ratings of Flex Pharma Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on FLEX PHARMA INC
12/01 FLEX PHARMA : Completes Patient Enrollment in Phase 2 Trial of Muscle-relaxing C..
11/29 FLEX PHARMA : Enrollment Completed in Flex Pharma's Phase 2 Exploratory Spastici..
11/29 FLEX PHARMA : Enrollment Completed in Flex Pharmas Phase 2 Exploratory Spasticit..
11/28 FLEX PHARMA : Enrollment Completed in Flex Pharma’s Phase 2 Exploratory Sp..
11/27 FLEX PHARMA : Arnold & Havas Media, Gear Communications Awarded HOTSHOT® Creativ..
11/09 FLEX PHARMA : Reports Positive Topline Data from Exploratory Phase 2 Trial of FL..
11/09 FLEX PHARMA : Reports Third Quarter 2017 Financial Results
11/08 FLEX PHARMA : to Report Third Quarter 2017 Results on November 6, 2017
11/06 FLEX PHARMA,INC. (NASDAQ : FLKS) Files An 8-K Results of Operations and Financia..
11/06 FLEX PHARMA : Management's Discussion and Analysis of Financial Condition and Re..
More news
Sector news : Bio Therapeutic Drugs
10:43a M&A dominates Europe share trading as oil leads gains
12/09 Tax-loss selling to pressure 2017's losers in December
11/30 GENMAB : and J&J 'love' partnership as some ponder takeover
11/27 MERCK AND : As Brexit looms, UK pitches new industry plan, wins support from Mer..
11/27 MERCK AND : As Brexit looms, UK pitches new industry plan, wins support from Mer..
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
11/06 Flex Pharma's (FLKS) CEO Bill McVicar on Q3 2017 Results - Earnings Call Tran..
11/06 Flex Pharma's FLX-787 shows positive effect in mid-stage study in ALS crampin..
11/06 Flex Pharma beats by $0.07, misses on revenue
09/12 Flex Pharma (FLKS) Presents At Rodman & Renshaw 19th Annual Global Investment..
09/06 Midday Gainers / Losers
Chart FLEX PHARMA INC
Duration : Period :
Flex Pharma Inc Technical Analysis Chart | FLKS | US33938A1051 | 4-Traders
Technical analysis trends FLEX PHARMA INC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 18,0 $
Spread / Average Target 403%
EPS Revisions
Managers
NameTitle
William K. McVicar President, Chief Executive Officer & Director
Christoph H. Westphal Chairman
John McCabe Chief Financial Officer & Treasurer
Thomas C. Wessel Chief Medical Officer
Peter Barton Hutt Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
FLEX PHARMA INC-29.55%64
GILEAD SCIENCES1.55%99 094
REGENERON PHARMACEUTICALS1.78%40 969
VERTEX PHARMACEUTICALS88.38%35 831
GENMAB1.79%11 452
BLUEBIRD BIO INC172.12%9 249